Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

69
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
69
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Drug Therapy01:28

Drug Therapy

158
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
158
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.9K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.9K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

807
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
807

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials.

American journal of preventive cardiology·2026
Same author

Capturing multi-disease states on a spectrum with machine learning and routine clinical data.

Med (New York, N.Y.)·2026
Same author

Remnant cholesterol - The transition from biomarker to risk factor.

Atherosclerosis·2026
Same author

Inclisiran in CKD: A Therapeutic Answer to a Persistent Treatment Gap.

Journal of the American Society of Nephrology : JASN·2026
Same author

Lipoprotein(a)-associated proteomic signature predicts cardiovascular disease in young adults.

The Journal of clinical investigation·2026
Same author

Associations of 10-year predicted ASCVD risk by the PREVENT equations with AI-analyzed coronary atherosclerotic plaque characteristics.

American journal of preventive cardiology·2026
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Related Experiment Video

Updated: Nov 25, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.1K

The rationale for combination therapy.

Robert S Rosenson1

  • 1Department of Medicine and Preventive Medicine, Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA. r-rosenson@northwestern.edu

The American Journal of Cardiology
|December 7, 2002
PubMed
Summary
This summary is machine-generated.

Combination lipid-altering therapy is crucial for managing coronary heart disease (CHD) patients with dyslipidemia. This approach, often using statins with other agents, effectively lowers LDL cholesterol and addresses HDL cholesterol and triglyceride levels for better outcomes.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.2K

Related Experiment Videos

Last Updated: Nov 25, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.1K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.2K

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Dyslipidemia management is key for coronary heart disease (CHD) patients.
  • Low-density lipoprotein (LDL) cholesterol reduction is the primary therapeutic goal per Adult Treatment Panel III guidelines.
  • Low high-density lipoprotein (HDL) cholesterol and elevated triglycerides are significant CHD risk factors.

Purpose of the Study:

  • To review the rationale for using combination lipid-altering therapy in dyslipidemia.
  • To highlight effective management strategies for dyslipidemia using combination therapies.
  • To emphasize the importance of addressing multiple lipid parameters beyond LDL cholesterol.

Main Methods:

  • Review of existing literature and clinical guidelines on dyslipidemia treatment.
  • Analysis of the benefits of LDL cholesterol reduction on CHD events and mortality.
  • Examination of the role of combination therapy involving statins with other lipid-lowering agents.

Main Results:

  • Combination therapy is increasingly vital for effective dyslipidemia management in CHD.
  • Targeting LDL cholesterol is primary, but addressing HDL and triglycerides offers additional benefits.
  • Statins combined with niacin, fibric acid derivatives, bile acid resins, or cholesterol absorption inhibitors are common strategies.

Conclusions:

  • Combination lipid-altering therapy is essential for comprehensive dyslipidemia treatment.
  • Aggressive management strategies are often necessary, frequently involving multiple drug classes.
  • Addressing aberrant lipoprotein subclasses and triglyceride levels improves outcomes in mixed dyslipidemias.